Sitagliptin lowers blood sugar by blocking an enzyme called DPP-4, which normally breaks down the gut hormones responsible for triggering insulin release after a meal. By keeping those hormones active longer, sitagliptin helps your body produce more insulin when blood sugar is high and dial back the hormone that raises it. It’s taken once daily for type 2 diabetes and is sold under the brand name Januvia.
The DPP-4 Enzyme and Incretin Hormones
When you eat, your gut releases two hormones: GLP-1 and GIP, collectively called incretins. Their job is to signal your pancreas to release insulin so your body can move sugar out of the bloodstream and into cells. The problem is that an enzyme called DPP-4 chews up these hormones within minutes of their release. In people with type 2 diabetes, this rapid breakdown means the incretin signal is too weak and too brief to adequately control blood sugar.
Sitagliptin binds to DPP-4 and blocks it from degrading GLP-1 and GIP. With the enzyme out of the way, circulating levels of both hormones rise and stay elevated long enough to do their work. This was first demonstrated in the early 1990s, when researchers showed that incubating human blood plasma with a DPP-4 inhibitor prevented GLP-1 from being broken down. Sitagliptin, approved in 2006, was the first drug in this class to reach the market.
What Happens in the Pancreas
The elevated incretin hormones act on two types of cells in the pancreas. Beta cells receive a stronger signal to release insulin, but only when blood sugar is already high. This glucose-dependent mechanism is important because it means sitagliptin carries a low risk of causing hypoglycemia on its own. Your body won’t dump insulin when your blood sugar is normal.
At the same time, sitagliptin reduces glucagon secretion from alpha cells. Glucagon is the hormone that tells your liver to release stored sugar into the bloodstream. By lowering glucagon levels, sitagliptin decreases the amount of sugar your liver produces between meals and after eating. The combined effect, more insulin when needed and less glucagon pushing sugar out of the liver, brings down both fasting blood sugar and the spikes that follow meals.
How Much It Lowers Blood Sugar
In six-month clinical trials, sitagliptin used alone reduced A1C levels by an average of 0.8 percentage points in patients starting around 8.1%. The effect scales with how uncontrolled blood sugar is at the start: patients with a baseline A1C between 7% and 8% saw a 0.6-point drop, while those starting at 9% or higher saw a 1.5-point reduction.
When added to metformin or another oral diabetes medication, sitagliptin typically shaves off an additional 0.7 percentage points. These reductions are modest compared to some other drug classes, which is why sitagliptin is often used as part of a combination regimen rather than the sole treatment for people who need a large A1C reduction.
Effects on Body Weight
Sitagliptin is generally classified as weight-neutral, meaning it doesn’t cause the weight gain associated with some older diabetes medications. In head-to-head comparisons with sulfonylureas, sitagliptin consistently comes out ahead: one post-hoc analysis of patients over 65 found sitagliptin reduced body weight by 1.7 kg while the sulfonylurea group gained 0.5 kg. A meta-analysis of over 1,300 patients confirmed a roughly 2 kg advantage for sitagliptin over sulfonylureas.
A large review of 18 randomized trials in overweight and obese patients found that sitagliptin alone produced an average weight loss of about 1 kg, and the combination of sitagliptin plus metformin produced a similar loss of about 1.1 kg. This isn’t dramatic weight loss by any measure, but for people switching from a medication that causes weight gain, even a neutral or slightly favorable effect matters.
How Long It Takes to Work
After you swallow a tablet, sitagliptin reaches peak levels in your blood within one to four hours. Its half-life is roughly 12 hours, which is long enough to maintain DPP-4 inhibition throughout the day on a single 100 mg dose. Blood sugar improvements after meals can begin within the first few days, but A1C changes, which reflect average blood sugar over two to three months, take several weeks to become apparent on lab work.
Dose Adjustments for Kidney Function
Your kidneys handle most of sitagliptin’s elimination, so reduced kidney function means the drug stays in your system longer. The standard dose is 100 mg once daily, but if your kidney filtration rate (eGFR) falls between 30 and 45, the dose drops to 50 mg. Below 30, it drops further to 25 mg. Your doctor will check kidney function before prescribing and periodically afterward to make sure the dose still fits.
Pancreatitis and Other Side Effects
The most closely watched risk with sitagliptin and all DPP-4 inhibitors is acute pancreatitis, an inflammation of the pancreas that causes severe, persistent abdominal pain often radiating to the back. Regulatory agencies in both the U.S. and UK have flagged this as a known possible reaction. The reporting rate is low, estimated between 1 in 1,000 and 1 in 100 patients, but the precise frequency is hard to pin down because few cases surfaced in clinical trials. In most reported cases, pancreatitis resolved after stopping the medication.
More common, everyday side effects tend to be mild: upper respiratory infections, nasal congestion, and headaches show up most frequently in trial data. Because sitagliptin stimulates insulin release only when blood sugar is elevated, the risk of low blood sugar is low when it’s used alone. That risk increases if you’re also taking insulin or a sulfonylurea, since those drugs push insulin out regardless of your current blood sugar level.
Where Sitagliptin Fits in Treatment
Sitagliptin occupies a middle ground in type 2 diabetes management. It’s not the most powerful A1C-lowering option, but its low risk of hypoglycemia, weight neutrality, and once-daily dosing make it practical for people who need a modest additional reduction or who can’t tolerate more aggressive medications. It’s often added on top of metformin when metformin alone isn’t enough, or used as a first-line option for people who can’t take metformin due to kidney issues or side effects. The oral tablet and lack of injection also make it a simpler choice for people who aren’t ready for injectable therapies like GLP-1 receptor agonists or insulin.